Hemophilia care in the new millennium
著者
書誌事項
Hemophilia care in the new millennium
(Advances in experimental medicine and biology, v. 489)
Kluwer Academic/Plenum Publishers, c2001
大学図書館所蔵 全13件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
" Hemophilia Care: an International Symposium in honor of Harold R. Roberts" - p. xi
内容説明・目次
内容説明
There should be, and in the best of cases there is, a synergy between basic research and patient care. However, this synergy is hard to develop because the techniques required to be a successful researcher are so different from the skills required to be an outstanding physician. Harold R. Roberts, M.D., of the University of North Carolina at Chapel Hill, is an example of a physician-researcher who has benefited from having his feet in both the world of patient care and the world of the laboratory: he has let clinical problems direct his basic research effort and conversely has adopted research advances in his care of patients. Dr. Roberts's long and continuing career has included many research and clinical advances. He was part of the first group to determine the amino acid sequence of the important thrombin inhibitor hirudin and part of the group that prepared the first cryoprecipitates which were the first alternative to plasma as therapy in hemophilia A. Dr. Roberts has made significant advances in understanding the protein chemistry behind hemophilia B; he was among the first researchers to identify some patients as not being completely deficient but instead as having measurable levels of protein and subsequently demonstrated that this protein was dysfunctional. This important advance led him to a classification scheme for patients into Cross Reacting Material (CRM) positive, negative, and reduced. Dr.
目次
- Preface. I: Infectious Disease Risk. 1. The Transfusion-Transmitted Viruses in Blood Transfusion
- N.L.C. Luban, R.F. Jubran. II: Unexplained Aspects of Hemophilia and Hemostasis. 2. Are Patients with Glanzmann Thrombasthenia and the Bernard-Soulier Syndrome Protected Against Atherosclerosis? A.T. Nurden, et al. 3. Factor V: Dr. Jeckyll and Mr. Hyde
- M. Kalafatis, K.G. Mann. III: Novel Approaches to Therapy. 4. Gene Therapy for Hemophilia B: AAV-Mediated Transfer of the Gene for Coagulation Factor IX to Human Muscle
- P.J. Larson, K.A. High. 5. Use of Prophylaxis to Prevent Complications of Hemophilia
- P.M. Mannucci, et al. 6. Factor VIII Inhibitors
- P. Lollar, et al. 7. Use of High Dose Factor VIIa in Hemophilia Patients
- U. Hedner. IV: Inhibitor Development in Hemophilia Patients. 8. The Incidence of Inhibitors in Hemophilia A and the Induction of Immune Tolerance
- E. Briet, M. Peters. 9. Mechanisms of B-Cell Tolerance
- M.G. Jacquemin, et al. 10. Mechanisms of Unresponsiveness: T- en B-Cell Mediated Mechanisms of Anergy
- R. Greenwood, J. Frelinger. 11. CD4+ T Cells Specific for Factor VIII as a Target for Specific Suppression of Inhibitor Production
- M.T. Reding, et al. 12. CD40L Pathway Blockade as an Approach to Immunotherapy
- L.C. Burkly. V: Abstracts. Contributors. Index.
「Nielsen BookData」 より